Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 325 of 521 entries
View as:

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

Phase: N/A Priority: Normal
NCT ID: NCT00573508 Org: User:
Start: 08/31/07 End: 07/31/08 Due: 07/31/09

Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00189722 Org: User:
Start: - End: 07/31/05 Due: 07/31/06

Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

Phase: N/A Priority: Normal
NCT ID: NCT02479399 Org: User:
Start: 07/17/14 End: 10/16/18 Due: 10/16/19

Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT00801957 Org: User:
Start: 03/31/03 End: 11/30/04 Due: 11/30/05

A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients

Phase: N/A Priority: Normal
NCT ID: NCT01118572 Org: User:
Start: 02/28/10 End: 11/30/10 Due: 11/30/11

Study of Continuous OSI-906 Dosing

Phase: N/A Priority: Normal
NCT ID: NCT00514007 Org: User:
Start: 06/18/07 End: 03/19/12 Due: 03/19/13

A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients

Phase: N/A Priority: Normal
NCT ID: NCT00956319 Org: User:
Start: 05/31/09 End: 11/30/10 Due: 11/30/11

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Phase: N/A Priority: Normal
NCT ID: NCT00889382 Org: User:
Start: 08/05/09 End: 08/25/14 Due: 08/25/15

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Phase: N/A Priority: Normal
NCT ID: NCT00826280 Org: User:
Start: 03/24/09 End: 07/15/10 Due: 07/15/11

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Phase: N/A Priority: Normal
NCT ID: NCT02211846 Org: User:
Start: 09/21/14 End: 09/21/15 Due: 09/21/16

A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00924989 Org: User:
Start: 12/01/09 End: 10/08/12 Due: 10/08/13

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01186861 Org: User:
Start: 03/04/11 End: 03/11/15 Due: 03/11/16

Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

Phase: N/A Priority: Normal
NCT ID: NCT02786979 Org: User:
Start: 07/31/10 End: 01/31/13 Due: 01/31/14

First in Men Study of Single Oral Doses of ASP1941 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01288885 Org: User:
Start: 11/30/06 End: 05/31/07 Due: 05/31/08

Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program

Phase: N/A Priority: Normal
NCT ID: NCT00371774 Org: User:
Start: 06/30/05 End: 05/31/08 Due: 05/31/09

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Phase: N/A Priority: Normal
NCT ID: NCT02500927 Org: User:
Start: 06/25/15 End: 06/09/17 Due: 06/09/18

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

Phase: N/A Priority: Normal
NCT ID: NCT01101906 Org: User:
Start: 01/10/11 End: 12/28/11 Due: 12/28/12

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Phase: N/A Priority: Normal
NCT ID: NCT00739453 Org: User:
Start: 10/23/08 End: 03/03/12 Due: 03/03/13

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients

Phase: N/A Priority: Normal
NCT ID: NCT01342016 Org: User:
Start: 04/30/11 End: 05/31/13 Due: 05/31/14

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Phase: N/A Priority: Normal
NCT ID: NCT00662909 Org: User:
Start: 03/28/08 End: 04/22/09 Due: 04/22/10

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00917254 Org: User:
Start: 05/31/09 End: 01/31/10 Due: 01/31/11

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Phase: N/A Priority: Normal
NCT ID: NCT00688688 Org: User:
Start: 04/25/08 End: 05/06/10 Due: 05/06/11

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Phase: N/A Priority: Normal
NCT ID: NCT00689104 Org: User:
Start: 04/28/08 End: 03/24/09 Due: 03/24/10

A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery

Phase: N/A Priority: Normal
NCT ID: NCT05457842 Org: User:
Start: 08/10/22 End: 09/20/22 Due: 09/20/23

A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea

Phase: N/A Priority: Normal
NCT ID: NCT00272285 Org: User:
Start: 01/31/06 End: 03/31/08 Due: 03/31/09